PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9092159

[Paraneoplastic opsoclonus].

H B Nielsen·G Nielsen·K Lühdorf
View original source ↗Export metadata ↓

Abstract

Opsoclonus occurs in a number of clinical settings, but its association with carcinomas in adult patients is rare. We present a case of paraneoplastic opsoclonus in a 63 year-old male who had a small-cell lung cancer. Even though paraneoplastic opsoclonus may be associated with an immunological response, there was no elevation of blood parameters associated with inflammation. The patient was treated with prednisolon without any clinical effect, and died only a few months after opsoclonus was diagnosed.

Explore related subjects

Carcinoma, Small CellDiagnosis, DifferentialHumansLung NeoplasmsMaleMiddle AgedOcular Motility DisordersParaneoplastic SyndromesCase ReportsEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H B Nielsen, G Nielsen, K Lühdorf. 1997-03-17. [Paraneoplastic opsoclonus].. https://pubmed.ncbi.nlm.nih.gov/9092159/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer.

The topoisomerase I inhibitor, topotecan, is approved for the treatment of recurrent small-cell lung cancer (SCLC) and ovarian cancer (OC). Patients with recurrent SCLC and OC typically experience multiple relapses and receive multiple rounds of chemotherapy. In these settings, disease stabilisation is considered a treatment benefit, and quality-of-life effects and cumulative toxicities of treatments should be considered. Many patients with recurrent cancer may be predisposed to treatment-related adverse events because of advanced age, renal impairment or extensive prior therapy. The standard regimen of topotecan, 1.5 mg/m(2) on days 1-5 of a 21-day cycle, has generally mild nonhaematological toxicity and a well-defined haematological toxicity profile characterised by reversible and noncumulative neutropenia. Alternative regimens may lower the incidence of haematological toxicities and maintain antitumour efficacy. Topotecan may provide physicians with a versatile therapeutic option for the treatment of patients with relapsed SCLC or OC.

Carcinoma, Small Cell↗